We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+12.03%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$293M
AUM Growth
+$32.6M
(+13%)
Cap. Flow
+$9.4M
Cap. Flow
% of AUM
3.21%
Top 10 Holdings %
Top 10 Hldgs %
94.86%
Holding
14
New
4
Increased
1
Reduced
7
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$35.1M |
| 2 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
+$28.7M |
| 3 |
Alkermes
ALKS
|
+$18M |
| 4 |
AnaptysBio
ANAB
|
+$10.4M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$6.26M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$28M |
| 2 |
Elanco Animal Health
ELAN
|
+$23.7M |
| 3 |
Biogen
BIIB
|
+$18.5M |
| 4 |
United Therapeutics
UTHR
|
+$6.96M |
| 5 |
McKesson
MCK
|
+$5.51M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
United Therapeutics
UTHR
$25.8B
| $40.6M | 13.85% |
460,944
-79,150
| -15% | -$6.96M |
|
|
2
Regeneron Pharmaceuticals
REGN
$78.5B
| $39.2M | 13.38% |
+104,420
| New | +$35.1M |
|
|
3
McKesson
MCK
$100B
| $35.2M | 12% |
254,330
-38,967
| -13% | -$5.51M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $33.9M | 11.57% |
313,556
+58,556
| +23% | +$6.26M |
|
|
5
Biogen
BIIB
$30B
| $32.6M | 11.13% |
109,904
-66,806
| -38% | -$18.5M |
|
6
Enanta Pharmaceuticals
ENTA
$366M
| $30.2M | 10.32% |
489,385
-9,489
| -2% | -$588K |
|
|
TARO
7
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $29.9M | 10.2% |
+339,819
| New | +$28.7M |
|
|
8
Alkermes
ALKS
$8.22B
| $18.5M | 6.3% |
+905,078
| New | +$18M |
|
|
SRGA
9
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $9.94M | 3.39% |
120,965
-8,712
| -7% | -$611K |
|
|
IVC
10
DELISTED
Invacare Corporation
IVC
| $7.94M | 2.71% |
880,402
-344,359
| -28% | -$2.89M |
|
|
11
Gilead Sciences
GILD
$162B
| $7.92M | 2.7% |
121,861
-429,854
| -78% | -$28M |
|
|
12
AnaptysBio
ANAB
$1.58B
| $7.16M | 2.44% |
+440,409
| New | +$10.4M |
|
|
AVNS
13
DELISTED
Avanos Medical
AVNS
| – | – |
-59,429
| Closed | -$2.23M |
|
|
14
Elanco Animal Health
ELAN
$13.2B
| – | – |
-892,620
| Closed | -$23.7M |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q4 2019 Portfolio in Review
As of Q4 2019, Krensavage Asset Management held 14 positions worth $293M, up 13% from $260M the previous quarter. Its ten largest holdings account for 95% of the portfolio.
Krensavage Asset Management deployed $9.4M of net new capital in Q4 2019, opening 4 new positions and adding to 1 existing holding. Its largest new stake was Regeneron Pharmaceuticals: 104,420 shares worth $39.2M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.
On the sell side, the largest reduction was Gilead Sciences, an estimated $28M trimmed.
- Krensavage Asset Management's largest Q4 2019 buy was Regeneron Pharmaceuticals: 104,420 shares worth $39.2M.
- Krensavage Asset Management added most to Alexion Pharmaceuticals in Q4 2019, an estimated $6.26M increase.
- Krensavage Asset Management's biggest Q4 2019 reduction was Gilead Sciences, cutting an estimated $28M.
- Krensavage Asset Management fully exited Elanco Animal Health in Q4 2019, selling an estimated $23.7M.
- Krensavage Asset Management's ten largest holdings make up 95% of its $293M portfolio in Q4 2019.
- Krensavage Asset Management opened 4 new positions and closed 2 in Q4 2019.
- Krensavage Asset Management's portfolio value rose 13% quarter-over-quarter to $293M.
Based on Krensavage Asset Management's 13F filing for Q4 2019, filed 18 Feb 2020.